Amgen Inc. (NASDAQ:AMGN) Shares Acquired by Deutsche Bank AG

Key Points

• Deutsche Bank AG increased its stake in Amgen Inc., acquiring an additional 52,734 shares, bringing its total holdings to 3,266,009 shares valued at approximately $1.02 billion.
• Amgen recently reported $6.02 earnings per share (EPS) for the last quarter, surpassing expectations and showing a year-over-year revenue growth of 9.4% to $9.18 billion.
• The company declared a quarterly dividend of $2.38 per share, leading to an annualized dividend yield of 3.3% and a payout ratio of 77.84%.

Deutsche Bank AG raised its stake in shares of Amgen Inc. (NASDAQ:AMGN - Free Report) by 1.6% in the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 3,266,009 shares of the medical research company's stock after acquiring an additional 52,734 shares during the period. Deutsche Bank AG owned approximately 0.61% of Amgen worth $1,017,525,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in AMGN. Capital World Investors raised its stake in Amgen by 1,292.0% during the 4th quarter. Capital World Investors now owns 6,495,710 shares of the medical research company's stock valued at $1,693,042,000 after acquiring an additional 6,029,058 shares during the last quarter. GAMMA Investing LLC increased its position in Amgen by 43,573.5% during the 1st quarter. GAMMA Investing LLC now owns 3,661,589 shares of the medical research company's stock worth $1,140,768,000 after purchasing an additional 3,653,205 shares during the period. Capital International Investors increased its position in Amgen by 40.1% during the 4th quarter. Capital International Investors now owns 12,212,065 shares of the medical research company's stock worth $3,182,843,000 after purchasing an additional 3,495,503 shares during the period. Northern Trust Corp increased its position in Amgen by 15.8% during the 4th quarter. Northern Trust Corp now owns 6,431,029 shares of the medical research company's stock worth $1,676,183,000 after purchasing an additional 875,254 shares during the period. Finally, Capital Research Global Investors increased its position in Amgen by 20.7% during the 4th quarter. Capital Research Global Investors now owns 4,890,092 shares of the medical research company's stock worth $1,274,553,000 after purchasing an additional 839,686 shares during the period. 76.50% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of equities research analysts recently weighed in on AMGN shares. UBS Group lowered their price target on Amgen from $326.00 to $317.00 and set a "neutral" rating on the stock in a report on Wednesday, August 6th. Cantor Fitzgerald reaffirmed a "neutral" rating and set a $305.00 price target on shares of Amgen in a report on Tuesday, June 24th. Bank of America boosted their target price on Amgen from $252.00 to $261.00 and gave the stock an "underperform" rating in a report on Wednesday, July 23rd. William Blair reaffirmed an "outperform" rating on shares of Amgen in a report on Tuesday, June 24th. Finally, Piper Sandler restated an "overweight" rating and set a $328.00 price target on shares of Amgen in a report on Friday, June 27th. Two analysts have rated the stock with a sell rating, twelve have given a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of "Hold" and a consensus target price of $303.76.

Insider Transactions at Amgen

In other news, SVP Rachna Khosla sold 1,500 shares of the firm's stock in a transaction that occurred on Thursday, June 5th. The stock was sold at an average price of $289.68, for a total value of $434,520.00. Following the completion of the sale, the senior vice president directly owned 8,162 shares of the company's stock, valued at $2,364,368.16. This trade represents a 15.52% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 0.69% of the stock is owned by corporate insiders.

Amgen Stock Down 0.5%

AMGN stock traded down $1.47 during trading on Monday, reaching $286.77. 519,442 shares of the company traded hands, compared to its average volume of 2,889,819. The company has a debt-to-equity ratio of 7.24, a quick ratio of 0.98 and a current ratio of 1.31. Amgen Inc. has a 12 month low of $253.30 and a 12 month high of $339.17. The company has a market capitalization of $154.38 billion, a price-to-earnings ratio of 23.47, a price-to-earnings-growth ratio of 2.49 and a beta of 0.49. The business has a 50 day simple moving average of $293.23 and a 200 day simple moving average of $292.81.

Amgen (NASDAQ:AMGN - Get Free Report) last announced its earnings results on Tuesday, August 5th. The medical research company reported $6.02 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $5.28 by $0.74. The firm had revenue of $9.18 billion for the quarter, compared to analyst estimates of $8.86 billion. Amgen had a return on equity of 174.71% and a net margin of 18.96%. The business's revenue was up 9.4% on a year-over-year basis. During the same quarter last year, the firm posted $4.97 EPS. On average, equities research analysts anticipate that Amgen Inc. will post 20.62 earnings per share for the current fiscal year.

Amgen Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, September 12th. Investors of record on Friday, August 22nd will be paid a dividend of $2.38 per share. This represents a $9.52 dividend on an annualized basis and a yield of 3.3%. The ex-dividend date is Friday, August 22nd. Amgen's dividend payout ratio (DPR) is currently 77.84%.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.